

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

A1500-M GLOSS BASE GREY BLUE AFNOR 1625

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name SDS code

: A1500-M GLOSS BASE GREY BLUE AFNOR 1625 : 13961625B

1.2 Relevant identified uses of the substance or mixture and uses advised against

| | Identified uses | |
|-------------------------|--|--|
| Paint. Professional use | Industrial use | |
| | Uses advised against | |
| All other uses | | |
| | . Oskumt hama asating fan sutarian was | |

Product use

: Solvent borne coating for exterior use.

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

1.4 Emergency telephone number

| National advisory body/Poison Center | | |
|--------------------------------------|------------------------|--|
| Telephone number | : (0551) 19240 | |
| <u>Supplier</u> | | |
| Telephone number | : +33 (0)5 34 01 34 01 | |
| | +33 (0)5 61 60 23 30 | |

Hours of operation

SECTION 2: Hazards identification

:

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Sens. 1, H317 STOT SE 3, H336 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue | : 21-10-2022 | 1/20 | AkzoNobel |

SECTION 2: Hazards identification

| 2.2 Label elements | | |
|---|----|--|
| Hazard pictograms | : | |
| | | |
| Signal word | : | Warning |
| Hazard statements | : | Flammable liquid and vapor. May cause an allergic skin reaction. May cause drowsiness or dizziness. Harmful to aquatic life with long lasting effects. |
| Precautionary statements | | |
| Prevention | : | Wear protective gloves. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Avoid breathing vapor. |
| Response | : | IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. If skin irritation or rash occurs: Get medical advice or attention. |
| Storage | : | Store in a well-ventilated place. Keep container tightly closed. Keep cool. |
| Disposal | : | Dispose of contents and container in accordance with all local, regional, national and international regulations. |
| Hazardous ingredients | : | 2-ethoxy-1-methylethyl acetate n-butyl acetate Hydroxyphenyl-benzotriazole derivatives Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate Polymeric Benzotriazole |
| Supplemental label elements | : | Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. |
| Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles | : | Not applicable. |
| Special packaging requirem | en | <u>ts</u> |
| Containers to be fitted with child-resistant fastenings | : | Not applicable. |
| Tactile warning of danger | : | Not applicable. |
| 2.3 Other hazards Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII | : | This mixture does not contain any substances that are assessed to be a PBT or a vPvB. |
| Other hazards which do not result in classification | : | None known. |



SECTION 3: Composition/information on ingredients

| 3.2 Mixtures : N | lixture | | | - |
|---|---|-----------|--|---------|
| Product/ingredient name | Identifiers | % | Regulation (EC) No. 1272/2008 [CLP] | Туре |
| -ethoxy-1-methylethyl acetate | EC: 259-370-9 CAS: 54839-24-6 Index: 603-177-00-8 | ≥10 - ≤25 | Flam. Liq. 3, H226 STOT SE 3, H336 | [1] [2] |
| n-butyl acetate | REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1 | ≥10 - ≤15 | Flam. Liq. 3, H226 STOT SE 3, H336 EUH066 | [1] [2] |
| 2-methoxy-1-methylethyl acetate | REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 | ≤5 | Flam. Liq. 3, H226 STOT SE 3, H336 | [1] [2] |
| Reaction mass of ethylbenzene and xylene | REACH #: 01-2119488216-32 | ≤3 | Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | [1] [2] |
| Hydroxyphenyl-benzotriazole derivatives | REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 | <1 | Skin Sens. 1, H317 Aquatic Chronic 2, H411 | [1] |
| Reaction mass of Bis (1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate | REACH #: 01-2119491304-40 EC: 915-687-0 CAS: 1065336-91-5 | ≤1 | Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1) | [1] |
| 4-methylpentan-2-one | EC: 203-550-1 CAS: 108-10-1 Index: 606-004-00-4 | ≤0.7 | Flam. Liq. 2, H225 Acute Tox. 4, H332 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336 EUH066 | [1] [2] |
| Polymeric Benzotriazole | CAS: 104810-47-1 | <1 | Skin Sens. 1, H317 Aquatic Chronic 2, H411 | [1] |
| Hydrocarbons, C10-C13, n- alkanes, isoalkanes, cyclics, < 2% aromatics | REACH #: 01-2119457273-39 EC: 918-481-9 | ≤0.55 | Asp. Tox. 1, H304 EUH066 | [1] [2] |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | REACH #: 01-2119979093-30 EC: 286-272-3 CAS: 85203-81-2 | ≤0.3 | Eye Irrit. 2, H319 Repr. 2, H361d (oral) Aquatic Chronic 3, H412 | [1] [2] |
| propylidynetrimethanol | EC: 201-074-9 CAS: 77-99-6 | ≤0.3 | Repr. 2, H361 | [1] |
| | | | See Section 16 for the full text of the H statements declared above. | |

| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue | : 21-10-2022 | 3/20 | AkzoNobel |

SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

| Eye contact | : | Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs. |
|----------------------------|---|---|
| Inhalation | : | Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. |
| Skin contact | : | Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse. |
| Ingestion | : | Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. |
| Protection of first-aiders | : | No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. |

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption

| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
|--------------------------------|--------------|----------------|-----------|
| Date of previous issue | : 21-10-2022 | 4/20 | AkzoNobel |

SECTION 4: First aid measures

through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains Hydroxyphenyl-benzotriazole derivatives, Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate, Polymeric Benzotriazole. May produce an allergic reaction.

Over-exposure signs/symptoms

| Eye contact | : No specific data. |
|--------------|---|
| Inhalation | : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness |
| Skin contact | : Adverse symptoms may include the following: irritation redness |
| Ingestion | : No specific data. |

4.3 Indication of any immediate medical attention and special treatment needed

| Notes to physician | Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled. |
|---------------------|---|
| Specific treatments | : No specific treatment. |

SECTION 5: Firefighting measures

| 5.1 Extinguishing media | | | |
|---|---|--|---|
| Suitable extinguishing media | : Use dry chemical, (| CO ₂ , water spray (fog) or foam. | |
| Unsuitable extinguishing media | : Do not use water je | t. | |
| 5.2 Special hazards arising f | from the substance or | mixture | |
| Hazards from the substance or mixture | In a fire or if heated the risk of a subseq lasting effects. Fire | nd vapor. Runoff to sewer may create , a pressure increase will occur and th juent explosion. This material is harm water contaminated with this material ng discharged to any waterway, sewer | e container may burst, with ful to aquatic life with long must be contained and |
| Hazardous combustion products | : Decomposition proc carbon dioxide carbon monoxide metal oxide/oxides | ducts may include the following materia | als: |
| 5.3 Advice for firefighters | | | |
| Special protective actions for fire-fighters | there is a fire. No a suitable training. M | e scene by removing all persons from t action shall be taken involving any pers love containers from fire area if this ca keep fire-exposed containers cool. | onal risk or without |
| Special protective equipment for fire-fighters | breathing apparatus mode. Clothing for | wear appropriate protective equipmer s (SCBA) with a full face-piece operate fire-fighters (including helmets, protec pean standard EN 469 will provide a ba | ed in positive pressure tive boots and gloves) |
| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
| Date of previous issue | : 21-10-2022 | 5/20 | AkzoNobel |

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

| on i oroonar probaationo, pro | fice and energency procedure |
|--------------------------------|---|
| For non-emergency personnel | : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment. |
| For emergency responders | : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |
| 6.2 Environmental precautions | : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities. |
| 6.3 Methods and materials fo | r containment and cleaning up |
| Small spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor. |
| Large spill | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth |

and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
 6.4 Reference to other sections
 See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

| Protective measures | history of skin sensitizati which this product is use Avoid breathing vapor or adequate ventilation. W Do not enter storage are Keep in the original cont material, kept tightly clos open flame or any other lighting and material han precautionary measures | anal protective equipment (see Sec on problems should not be employ d. Do not get in eyes or on skin or mist. Avoid release to the environ ear appropriate respirator when ve as and confined spaces unless add ainer or an approved alternative ma ed when not in use. Store and use ignition source. Use explosion-pro dling) equipment. Use only non-sp against electrostatic discharges. E be hazardous. Do not reuse conta | red in any process in clothing. Do not ingest. ment. Use only with ntilation is inadequate. equately ventilated. ade from a compatible e away from heat, sparks, oof electrical (ventilating, parking tools. Take Empty containers retain |
|--|---|--|--|
| Advice on general occupational hygiene | handled, stored and proc eating, drinking and smo | oking should be prohibited in areas cessed. Workers should wash han king. Remove contaminated cloth ng eating areas. See also Section neasures. | nds and face before ing and protective |
| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
| Date of previous issue | : 21-10-2022 | 6/20 | AkzoNobel |

SECTION 7: Handling and storage

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

| Ca | | Notification and MAPP threshold | Safety report threshold |
|----|----|---------------------------------|-------------------------|
| P | 5c | 5000 tonne | 50000 tonne |

7.3 Specific end use(s)

F

| Recommendations | : Not available. |
|---------------------------|------------------|
| ndustrial sector specific | : Not available. |

Industrial sector specific solutions

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

| Product/ingredient r | ame | Exposure limit values | | |
|---------------------------------|--------------|---|-----------|--|
| ₽-ethoxy-1-methylethyl acetate | | DFG MAC-values list (Germany, 7/2019). Absorbed through skin. PEAK: 240 mg/m³, 4 times per shift, 15 minutes. PEAK: 40 ppm, 4 times per shift, 15 minutes. TWA: 120 mg/m³ 8 hours. TWA: 20 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). Absorbed through skin. PEAK: 240 mg/m³ 15 minutes. PEAK: 40 ppm 15 minutes. TWA: 120 mg/m³ 8 hours. TWA: 20 ppm 8 hours. | | |
| n-butyl acetate | | DFG MAC-values list (Germany, 7/2019). PEAK: 960 mg/m³, 4 times per shift, 15 minutes. PEAK: 200 ppm, 4 times per shift, 15 minutes. TWA: 480 mg/m³ 8 hours. TWA: 100 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). TWA: 300 mg/m³ 8 hours. TWA: 62 ppm 8 hours. PEAK: 600 mg/m³ 15 minutes. PEAK: 124 ppm 15 minutes. | | |
| 2-methoxy-1-methylethyl acetate | | TRGS 900 OEL (Germany, 6/2018). TWA: 270 mg/m³ 8 hours. PEAK: 270 mg/m³ 15 minutes. TWA: 50 ppm 8 hours. PEAK: 50 ppm 15 minutes. DFG MAC-values list (Germany, 7/2018). TWA: 50 ppm 8 hours. PEAK: 50 ppm, 4 times per shift, 15 minutes. TWA: 270 mg/m³ 8 hours. | | |
| ate of issue/Date of revision | : 27-10-2022 | Version : 1.02 | | |
| ate of previous issue | :21-10-2022 | 7/20 | AkzoNobel | |

| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | LOSS BASE GRET BLUE AFNOR 1025 | | |
|--|--|--|--|
| SECTION 8: Exposure controls/personal protection | | | |
| | PEAK: 270 mg/m³, 4 times per shift, 15 minutes. | | |
| Reaction mass of ethylbenzene and xylene | DFG MAC-values list (Germany, 7/2019). Absorbed through skin. PEAK: 440 mg/m³, 4 times per shift, 15 minutes. PEAK: 100 ppm, 4 times per shift, 15 minutes. TWA: 220 mg/m³ 8 hours. TWA: 50 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). Absorbed through skin. PEAK: 880 mg/m³ 15 minutes. PEAK: 200 ppm 15 minutes. TWA: 440 mg/m³ 8 hours. TWA: 100 ppm 8 hours. | | |
| 4-methylpentan-2-one | DFG MAC-values list (Germany, 7/2019). Absorbed through skin. PEAK: 166 mg/m³, 4 times per shift, 15 minutes. PEAK: 40 ppm, 4 times per shift, 15 minutes. TWA: 83 mg/m³ 8 hours. TWA: 20 ppm 8 hours. TRGS 900 OEL (Germany, 3/2020). Absorbed through skin. PEAK: 166 mg/m³ 15 minutes. PEAK: 40 ppm 15 minutes. TWA: 83 mg/m³ 8 hours. TWA: 83 mg/m³ 8 hours. | | |
| Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, < 2% aromatics | DFG MAC-values list (Germany, 7/2019). TWA: 50 ppm 8 hours. TWA: 300 mg/m ³ 8 hours. PEAK: 100 ppm, 4 times per shift, 15 minutes. PEAK: 600 mg/m ³ , 4 times per shift, 15 minutes. | | |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | DFG MAC-values list (Germany, 7/2019). TWA: 2 mg/m³ 8 hours. Form: inhalable fraction PEAK: 4 mg/m³, 4 times per shift, 15 minutes. Form: inhalable fraction PEAK: 0.4 mg/m³, 4 times per shift, 15 minutes. Form: respirable fraction TWA: 0.1 mg/m³ 8 hours. Form: respirable fraction | | |
| procedures atmosphere of of the ventilat protective equ the following: the assessme limit values an atmospheres of exposure to (Workplace a for the measu | a contains ingredients with exposure limits, personal, workplace or biological monitoring may be required to determine the effectiveness ion or other control measures and/or the necessity to use respiratory uipment. Reference should be made to monitoring standards, such as European Standard EN 689 (Workplace atmospheres - Guidance for ent of exposure by inhalation to chemical agents for comparison with nd measurement strategy) European Standard EN 14042 (Workplace - Guide for the application and use of procedures for the assessment o chemical and biological agents) European Standard EN 482 tmospheres - General requirements for the performance of procedures urement of chemical agents) Reference to national guidance or methods for the determination of hazardous substances will also be | | |

DNELs/DMELs



| NetDNEL Long term Dermalbw/day 3.4 mg/kg bw/daypopulation General populationSystemic SystemicDNEL Long term DermalLong term Dermal7 mg/kg bw/dayWorkersSystemicDNEL Long term InhalationLong term Inhalation12 mg/m³ general populationGeneral populationSystemicDNEL Long term InhalationLong term Inhalation102.34 mg/ m³General populationLocalDNEL Long term InhalationDNEL InhalationLong term m³ m³General populationLocalDNEL Long term Inhalation DNEL InhalationB59.7 mg/ m³ General populationGeneral populationLocalDNEL Short term Inhalation DNEL Short term Inhalation DNEL Inhalation DNEL Short term InhalationB69.7 mg/ General general populationGeneral populationLocalDNEL Inhalation Inhalation DNEL DNEL DNEL Long term Oral1.6 mg/kg bw/dayGeneral populationSystemic populationReaction mass of ethylbenzene and xyleneDNEL Long term Oral1.6 mg/kg bw/dayGeneral populationSystemic populationDNEL Long term Dermal Inhalation DNEL DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation108 mg/kg bw/dayGeneral gopulationSystemic populationDNEL Long term Dermal Inhalation Inhalation DNEL DNEL DNEL DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL DNEL< | Product/ingredient name | Туре | Exposure | Value | Population | Effects |
|--|------------------------------------|-------|------------------|------------------------|--|------------|
| DNEL butyl acetateDNEL DNEL butyl acetateCong term Dermal butyl acetateSystemic butyl acetateSystemic butyl acetaten-butyl acetateDNEL DNEL butyl acetateDNEL DNEL butyl acetateCong term Dermal butyl acetateSystemic butyl acetateSystemic population DNEL butyl acetateSystemic population butyl acetateSystemic population population DNEL butyl acetateSystemic population population population DNEL butyl acetateSystemic population population population DNEL butyl acetateSystemic population population population DNEL butyl acetateSystemic population populat | | DNEL | Long term Oral | 13.1 mg/ | General | Systemic |
| Image: constraint of the second sec | | | _ | | | - |
| NELLong term Dermal inhalation103 mg/kg bw/dayWorkersSystemicDNELLong term inhalation181 mg/m³ populationGeneral populationSystemicDNELShort term inhalation365 mg/m³ populationGeneral populationSystemicDNELShort term inhalation608 mg/m³ bw/dayGeneral populationSystemicn-butyl acetateDNELLong term Oral inhalation3.4 mg/kg bw/dayGeneral populationSystemicn-butyl acetateDNELLong term Oral inhalation12 mg/m³ populationGeneral populationSystemicn-butyl acetateDNELLong term Oral inhalation12 mg/m³ populationGeneral populationSystemicn-butyl acetateDNELLong term Dermal inhalation12 mg/m³ populationGeneral populationSystemicDNELLong term inhalation12 mg/m³ populationGeneral populationSystemicDNELLong term inhalation102.34 mg populationCeneral populationLocalDNELShort term inhalation859.7 mg/ populationGeneral populationSystemic populationDNELShort term inhalation960 mg/m³WorkersSystemic populationDNELLong term Oral inhalation1.6 mg/kg populationGeneral populationSystemic populationDNELLong term Oral inhalation1.6 mg/kg populationGeneral populationSystemic population | | DNEL | Long term Dermal | | | Systemic |
| n-butyl acetate DNEL DNEL Long term inhalation DNEL 181 mg/m ³ (General population DNEL General population Botot term inhalation DNEL Systemic DNEL n-butyl acetate DNEL Long term inhalation DNEL Systemic DNEL Systemic DNEL Systemic DNEL Systemic DNEL Systemic DNEL DNEL Long term inhalation 3.4 mg/kg DNEL General DNEL Systemic Dopulation DNEL Long term Dermal 3.4 mg/kg DNEL General DNEL Systemic Dopulation DNEL Long term Dermal 3.4 mg/kg DNEL General DNEL Systemic Dopulation DNEL Long term Inhalation 12.3 mg/m ² DNEL General DNEL Systemic DNEL Long term 102.34 mg/ Inhalation General population Systemic Dovekers Systemic Dovekers DNEL Long term 480 mg/m ² General population Local DNEL Long term 660 mg/m ² General population Systemic DNEL Long term 660 mg/m ² General population Systemic DNEL Long term 660 mg/m ² General population S | | | | | | |
| DNEL Inhalation Inhalation Inhalation Inhalation181 mg/m² mg/m² Sceneral population WorkersSystemic systemic populationn-butyl acetateDNEL Short term Inhalation365 mg/m² Beneral populationGeneral population populationSystemic populationn-butyl acetateDNEL Long term Oral3.4 mg/kg Beneral DNEL Long term OralGeneral populationSystemic populationn-butyl acetateDNEL Long term Oral3.4 mg/kg Beneral DNEL Long term DermalGeneral populationSystemic populationn-butyl acetateDNEL Long term Dermal3.4 mg/kg Beneral DNEL Long term DermalGeneral populationSystemic populationn-butyl acetateDNEL Long term OralLong term Inhalation12 mg/m² Beneral populationSystemic populationnNEL InhalationLong term Inhalation102.34 mg/ m² Beneral populationGeneral populationSystemic populationDNEL InhalationShort term Inhalation859.7 mg Beneral populationGeneral populationSystemic populationDNEL InhalationShort term Inhalation960 mg/m² WorkersWorkersSystemic populationDNEL InhalationLong term Oral1.6 mg/kg BW/dayGeneral populationSystemic populationPNEL InhalationLong term Oral1.6 mg/kg BW/dayGeneral populationSystemic populationPNEL InhalationLong term Oral1.6 mg/kg BW/dayG | | DNEL | Long term Dermal | | Workers | Systemic |
| Inhalation Inhalation InhalationInhalation 302 mg/m³population WorkersSystemic population Morkersn-butyl acetateDNEL Inhalation InhalationSoft mg/m³ InhalationGeneral 3.4 mg/kg WorkersSystemic populationn-butyl acetateDNEL InhalationLong term Oral Inhalation3.4 mg/kg WorkersGeneral populationSystemic populationn-butyl acetateDNEL InhalationLong term Dermal Inhalation3.4 mg/kg WorkersGeneral populationSystemic populationDNEL InhalationLong term Dermal Inhalation12 mg/m³ WorkersGeneral populationSystemic populationDNEL InhalationLong term Inhalation102.34 mg/ m³ MorkersGeneral populationSystemic populationDNEL InhalationLong term Inhalation102.34 mg/ m³ MorkersGeneral populationLocal populationDNEL InhalationDNEL InhalationSystemic m³ m³Local populationLocal populationDNEL InhalationLong term m³ m³Beneral populationSystemic populationDNEL InhalationLong term m³ m³General populationSystemic populationDNEL InhalationLong term Oral Inhalation16 mg/m³ WorkersSystemic populationDNEL InhalationLong term Oral Inhalation16 mg/kg populationSystemic populationDNEL InhalationLong term Dermal Inhalation108 mg/kg Beneral <td></td> <td></td> <td>Long torm</td> <td></td> <td>Conorol</td> <td>Sustamia</td> | | | Long torm | | Conorol | Sustamia |
| DNEL Inhalation DNELDNEL Short term | | DNEL | | 101 mg/m² | | Systemic |
| Inhalation Inhalation InhalationInhalation Short term Inhalation DNELShort term Short term Inhalation DNELGeneral population Short term Inhalation DNELSystemic populationn-butyl acetateDNEL DNELLong term Oral Long term Dermal3.4 mg/kg WorkersGeneral population General populationSystemic Systemic populationn-butyl acetateDNEL Long term DermalLong term Dermal Inhalation Inhalation Inhalation3.4 mg/kg WorkersGeneral populationSystemic SystemicDNEL Long term Inhalation Inhalation Inhalation Inhalation102.34 mg/ WorkersGeneral populationSystemic Local Inhalation Inhalation Inhalation InhalationGeneral populationSystemic Inhalation WorkersDNEL Long term Inhalation Inhalation Inhalation InhalationBS9.7 mg/ WorkersGeneral populationSystemic Inhalation Inhalation Inhalation MorkersLocal Inhalation MorkersLocal Inhalation Inhalation Inhalation InhalationSystemic MorkersSystemic InhalationDNEL Inhalation Inhalation InhalationDNEL Long term Dermal Inhalation1.6 mg/kg WorkersGeneral SystemicSystemicDNEL Inhalation InhalationDNEL Long term Dermal Inhalation1.6 mg/kg WorkersGeneral SystemicSystemicDNEL Inhalation DNEL InhalationDNEL Long term Dermal Inhalation1.8 mg/m Bo mg/mWorkersSystemicDNEL Inhalation DN | | DNEI | | 302 mg/m^3 | | Systemic |
| DNELShort term inhalation365 mg/m² population WorkersGeneral Systemic population WorkersSystemic Systemicn-butyl acetateDNELLong term Oral3.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal3.4 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal7 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation12 mg/m² m³General populationSystemic populationDNELLong term Inhalation10: 34 mg/ m³General populationSystemic populationDNELLong term Inhalation10: 34 mg/ m³General populationLocalDNELLong term Inhalation10: 34 mg/ m³General populationLocalDNELShort term Inhalation859.7 mg/ m³General populationLocalDNELShort term Inhalationm³General populationSystemic populationDNELShort term Inhalation16 mg/kg bord termGeneral populationSystemic populationDNELLong term Oral1.6 mg/kg bord termGeneral populationSystemic populationDNELLong term Oral1.6 mg/kg bord termGeneral populationSystemic populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystemic SystemicDNELLong term Dermal Inhalation <td></td> <td>DILLE</td> <td></td> <td>002 mg/m</td> <td>Wontoro</td> <td>Cyclonno</td> | | DILLE | | 002 mg/m | Wontoro | Cyclonno |
| n-butyl acetateImhalationImhalationIopulationSystemicn-butyl acetateDNELShort term68 mg/m²GeneralSystemicDNELLong term Oral3.4 mg/kgGeneralSystemicDNELLong term Dermal3.4 mg/kgGeneralSystemicDNELLong term Dermal7 mg/kgWorkersSystemicDNELLong term Dermal12 mg/m²GeneralSystemicDNELLong term12 mg/m²GeneralSystemicDNELLong term48 mg/m²WorkersSystemicInhalation102.34 mg/GeneralLocalDNELLong term480 mg/m²WorkersLocalInhalation102.34 mg/GeneralLocalDNELLong term480 mg/m²WorkersLocalInhalationm²mg/m²WorkersLocalDNELShort term859.7 mg/GeneralSystemicInhalationm²mg/m²WorkersLocalDNELShort term960 mg/m²WorkersSystemicInhalationm²16 mg/m²SystemicDNELLong term Oral1.6 mg/kgGeneralSystemicInhalationDNELLong term14.8 mg/m²GeneralSystemicDNELLong term Oral1.6 mg/kgGeneralSystemicInhalationDNELLong term Oral1.8 mg/m²GeneralSystemicDNELLong term Dermal108 mg/kgGeneral <t< td=""><td></td><td>DNEL</td><td></td><td>365 mg/m³</td><td>General</td><td>Systemic</td></t<> | | DNEL | | 365 mg/m ³ | General | Systemic |
| n-butyl acetate n-butyl acetate DNEL Long term Oral 3.4 mg/kg General population Systemic population n-butyl acetate DNEL Long term Dermal 3.4 mg/kg General population Systemic DNEL Long term Dermal 7 mg/kg Workers Systemic Systemic DNEL Long term 12 mg/m² General population Systemic Systemic DNEL Long term 48 mg/m² Workers Systemic Systemic DNEL Long term 102.34 mg/ General population Workers Local Inhalation m³ General population Workers Local Inhalation m³ Workers Local Inhalation DNEL Long term 689.7 mg/ General population Systemic Inhalation m³ 960 mg/m³ Workers Systemic DNEL Short term 960 mg/m³ Workers Systemic Inhalation DNEL Long term Oral 1.6 mg/kg Seneral Systemic | | | Inhalation | _ | population | |
| n-butyl acetate DNEL Long term Oral 3.4 mg/kg General Systemic population General Systemic bw/day DNEL Long term Dermal Drema DNEL Long term Dermal Drema Dr | | DNEL | | 608 mg/m ³ | Workers | Systemic |
| * bw/day population Systemic DNEL Long term Dermal DNEL Long term Dermal DNEL 3.4 mg/kg bw/day population General bw/day Systemic DNEL Long term Inhalation 12 mg/m ³ General population Systemic DNEL Long term Inhalation 48 mg/m ³ Workers Systemic DNEL Long term Inhalation 102.34 mg/ m ³ General population Systemic DNEL Long term 102.34 mg/ Inhalation General population Local DNEL Long term 480 mg/m ³ Workers Local Inhalation m ³ general population Local Inhalation DNEL Short term 859.7 mg/ Inhalation General population Systemic DNEL Short term 960 mg/m ³ Workers Systemic Inhalation m ³ DNEL Long term Oral 1.6 mg/kg General population Systemic DNEL Long term Dermal 108 mg/kg General population Systemic Systemic DNEL | | | | | | |
| Image: Product of the system is a system is possible of the system is possible o | n-butyl acetate | DNEL | Long term Oral | | | Systemic |
| PointPointPointPointDNELLong term Dermal7 mg/kg bw/dayWorkersSystemicDNELLong term12 mg/m³General populationSystemicDNELLong term48 mg/m³WorkersSystemicDNELLong term102.34 mg/ m³General populationLocal populationDNELLong term480 mg/m³General populationLocalDNELShort term859.7 mg/ inhalationGeneral populationLocalDNELShort term859.7 mg/ inhalationGeneral populationSystemicDNELShort term859.7 mg/ inhalationGeneral populationSystemicDNELShort term960 mg/m³WorkersLocalInhalationm³WorkersSystemicDNELShort term960 mg/m³WorkersSystemicDNELLong term1.6 mg/kg populationGeneral populationSystemicDNELLong term1.6 mg/kg populationSystemicDNELLong term17 mg/m³WorkersSystemicDNELLong term17 mg/m³WorkersSystemicDNELLong term17 mg/m³WorkersSystemicDNELLong term108 mg/kg bw/dayGeneral populationSystemicDNELLong term108 mg/kg bw/dayWorkersSystemicDNELLong term108 mg/kg bw/dayGeneral populationSystemicD | | | Lengtern Dermal | | | Curata mia |
| DNELLong term Dermal ImplationTy mg/kg bw/dayWorkersSystemic systemicDNELLong term12 mg/m³ poulationGeneral poulationSystemicDNELLong term102.34 mg/ m³General poulationLocalDNELLong term102.34 mg/ m³General poulationLocalDNELLong term480 mg/m³WorkersLocalInhalationm³General poulationLocalDNELLong term480 mg/m³WorkersLocalDNELLong term859.7 mg/ poulationGeneral poulationLocalDNELShort term859.7 mg/ m³General poulationLocalDNELShort term960 mg/m³WorkersSystemic poulationDNELShort term960 mg/m³WorkersSystemic poulationDNELLong term1.6 mg/kg bw/dayGeneral poulationSystemic poulationDNELLong term1.6 mg/kg bw/dayGeneral poulationSystemic poulationDNELLong term Dermal108 mg/kg bw/dayGeneral poulationSystemic poulationDNELLong term Dermal108 mg/kg bw/dayWorkersSystemic poulationDNELLong term Dermal108 mg/kg bw/dayWorkersSystemic poulationDNELLong term Dermal108 mg/kg bw/dayWorkersSystemic poulationDNELLong term Dermal180 mg/m3WorkersSystemic poulation | | DNEL | Long term Dermai | | | Systemic |
| 4-methylpentan-2-one DNEL Long term Inhalation bw/day 12 mg/m³ General population Systemic NRL Long term Inhalation 102.34 mg/ m³ General population Local Workers Local DNEL Long term Inhalation 102.34 mg/ m³ General population Local DNEL Long term Inhalation 102.34 mg/ m³ General population Local DNEL Short term Inhalation 859.7 mg/ Inhalation General population Local DNEL Short term Inhalation 960 mg/m³ Workers Local DNEL Short term Inhalation 960 mg/m³ Workers Local DNEL Short term 960 mg/m³ Workers Systemic DNEL Long term Oral 1.6 mg/kg General population Systemic DNEL Long term Oral 1.6 mg/kg General population Systemic DNEL Long term Dermal 108 mg/kg General population Systemic DNEL Long term Dermal 108 mg/kg General population Systemic DNEL Long term Dermal 108 mg/kg Workers Systemic DNEL Long term Dermal 108 mg/kg Workers Systemic DNEL Long term Derm | | DNEI | Long term Dermal | | | Systemic |
| DNEL InhalationLong term Inhalation12 mg/m³ opulation populationSystemic populationDNEL InhalationDNEL InhalationLong term Inhalation48 mg/m³WorkersSystemicDNEL InhalationDNEL InhalationLong term m³480 mg/m³General populationLocalDNEL InhalationDNEL InhalationShort term Inhalation859.7 mg/ general populationGeneral populationLocalDNEL InhalationShort term Inhalation859.7 mg/ general populationGeneral populationSystemicDNEL InhalationShort term Inhalation960 mg/m³WorkersSystemicDNEL InhalationDNEL InhalationLocal populationSystemicLocalDNEL InhalationDNEL InhalationSort term InhalationGeneral populationSystemicDNEL InhalationDNEL InhalationDNEL InhalationGeneral populationSystemicDNEL InhalationDNEL Inhalation1.6 mg/kg General populationGeneral populationSystemicDNEL InhalationDNEL InhalationDNEL InhalationGeneral populationSystemicDNEL InhalationDNEL Inhalation108 mg/kg Bw/dayGeneral populationSystemicDNEL InhalationDNEL InhalationSystemicGeneral populationSystemicDNEL InhalationDNEL Inhalation289 mg/m³WorkersSystemicDNEL <br< td=""><td></td><td>DINCE</td><td>Long term Derma</td><td></td><td>WOINCIS</td><td>Oysternie</td></br<> | | DINCE | Long term Derma | | WOINCIS | Oysternie |
| Inhalation Long term InhalationDown 48 mg/m³population WorkersSystemicDNEL InhalationDNEL Long term Inhalation102.34 mg/ populationGeneral populationLocal populationDNEL InhalationDNEL InhalationLong term Inhalation480 mg/m³WorkersLocalDNEL InhalationDNEL Short termS59.7 mg/ InhalationGeneral populationLocalDNEL Short termShort term Inhalation859.7 mg/ InhalationGeneral populationSystemic populationDNEL Short termShort term Inhalation960 mg/m³WorkersLocalDNEL InhalationDNEL InhalationI.6 mg/kg BeneralGeneral Systemic InhalationSystemic populationDNEL InhalationDNEL InhalationLong term Inhalation1.6 mg/kg BeneralGeneral Systemic populationDNEL InhalationDNEL InhalationLong term InhalationGeneral Systemic populationSystemic populationDNEL InhalationDNEL InhalationLong term Permal Ithalation108 mg/kg WorkersGeneral SystemicDNEL InhalationDNEL Inhalation289 mg/m³WorkersSystemic populationDNEL InhalationIong term Dermal Inhalation289 mg/m³WorkersSystemic populationDNEL InhalationIong term Dermal Inhalation180 mg/kg Bow/dayGeneral SystemicSystemic populationDNEL Inhalation | | DNEL | Long term | | General | Systemic |
| Inhalation Long term Inhalation00DNEL Long term Inhalation102.34 mg/ populationLocalDNEL InhalationDNEL InhalationLong term Inhalation480 mg/m³General populationLocalDNEL InhalationDNEL Short term InhalationS59.7 mg/ m³General populationLocalDNEL Short term InhalationDNEL Short termS59.7 mg/ general populationGeneral populationSystemic populationDNEL Short term InhalationDNEL Short termShort term g60 mg/m³General populationSystemic populationDNEL InhalationDNEL InhalationShort term populationGeneral populationSystemic populationDNEL InhalationDNEL InhalationLong term Inhalation1.6 mg/kg populationSystemic populationDNEL InhalationDNEL InhalationLong term Inhalation108 mg/kg populationSystemic populationDNEL InhalationLong term Dermal Inhalation108 mg/kg populationSystemic populationDNEL InhalationShort term Inhalation289 mg/m³ WorkersWorkersSystemic population4-methylpentan-2-oneDNEL InhalationLong term Dermal Inhalation1.2 mg/kg bw/dayGeneral gopulationSystemic population4-methylpentan-2-oneDNEL InhalationLong term Dermal Inhalation1.2 mg/kg bw/dayGeneral gopulationSystemic population0 <td></td> <td></td> <td></td> <td><u> </u></td> <td></td> <td>,</td> | | | | <u> </u> | | , |
| NELLong term inhalation102.34 mg/ m²General populationLocalDNELLong term inhalation480 mg/m³WorkersLocalDNELShort term inhalation859.7 mg/ populationGeneral populationLocalDNELShort term inhalation859.7 mg/ populationGeneral populationSystemic populationDNELShort term inhalation960 mg/m³WorkersLocalDNELShort term inhalation960 mg/m³WorkersSystemicDNELShort term inhalation960 mg/m³WorkersSystemicDNELCong term Oral inhalation1.6 mg/kg populationGeneral populationSystemicDNELLong term Oral inhalation1.6 mg/kg populationGeneral populationSystemicDNELLong term Oral inhalation1.6 mg/kg populationGeneral populationSystemicDNELLong term Dermal inhalation108 mg/kg populationGeneral populationSystemicDNELLong term Dermal inhalation108 mg/kg populationGeneral populationSystemicDNELShort term inhalation289 mg/m³WorkersLocalDNELShort term inhalation289 mg/m³WorkersSystemicDNELLong term Dermal inhalation4.2 mg/kg generalGeneral SystemicSystemicDNELLong term Dermal inhalation1.8 mg/kg generalGeneral SystemicSystemicDN | | DNEL | | 48 mg/m³ | Workers | Systemic |
| Inhalationm³ 480 mg/m³population WorkersLocalDNELLong term480 mg/m³WorkersLocalInhalationm³general populationLocalDNELShort term859.7 mg/ inhalationGeneral populationSystemic populationDNELShort term960 mg/m³WorkersLocalInhalationm³960 mg/m³WorkersLocalDNELShort term960 mg/m³WorkersLocalInhalationm³960 mg/m³WorkersSystemicInhalationDNELShort term960 mg/m³WorkersSystemicInhalationDNELLong term Oral1.6 mg/kgGeneral populationSystemicDNELLong term14.8 mg/m³General populationSystemicDNELLong term Dermal108 mg/kgGeneral populationSystemicDNELLong term Dermal108 mg/kgGeneral populationSystemicDNELLong term Dermal180 mg/kgWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersLocalDNELShort term Inhalation289 mg/m³WorkersSystemicDNELLong term Dermal4.2 mg/kgGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSystemicDNELLong te | | | | _ | | - |
| DNEL InhalationLong term Inhalation480 mg/m³ WorkersWorkersLocalDNEL InhalationShort term Inhalation859.7 mg/ BS9.7 mg/ General populationGeneral populationSystemic populationDNEL InhalationShort term Inhalation960 mg/m³WorkersLocalDNEL InhalationShort term Inhalation960 mg/m³WorkersLocalDNEL InhalationShort term Inhalation960 mg/m³WorkersSystemicDNEL InhalationShort term Inhalation960 mg/m³WorkersSystemicDNEL InhalationDNEL InhalationLong term Oral1.6 mg/kg bw/dayGeneral populationSystemicDNEL InhalationDNEL InhalationLong term Inhalation77 mg/m³WorkersSystemicDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSystemicDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSystemicDNEL InhalationDNEL InhalationShort term Inhalation289 mg/m³WorkersSystemicDNEL InhalationDNEL InhalationLong term Oral Inhalation4.2 mg/kg General populationSystemicDNEL InhalationDNEL InhalationLong term Dermal InhalationGeneral SystemicSystemicDNEL InhalationLong term Dermal Inhalation4.2 mg/kg General Systemic <td< td=""><td></td><td>DNEL</td><td></td><td></td><td></td><td>Local</td></td<> | | DNEL | | | | Local |
| Inhalation0DNELShort term inhalation859.7 mg/ m³General populationLocal populationDNELShort term inhalation859.7 mg/ m³General populationSystemic populationDNELShort term inhalation960 mg/m³WorkersLocalDNELShort term inhalation960 mg/m³WorkersSystemicDNELShort term inhalation960 mg/m³WorkersSystemicDNELShort term inhalation960 mg/m³WorkersSystemicDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystemicDNELLong term inhalation77 mg/m³WorkersSystemicDNELLong term inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationSystemicDNELShort term inhalation289 mg/m³WorkersSystemicDNELShort term inhalation289 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal inhalation1.8 mg/ populationSystemicDNELLong term Dermal inhalationMorkersSystemicDNELLong term Dermal inhalation4.2 mg/kg populationSystemic | | | | | | |
| NRL short term inhalationShort term inhalation859.7 mg/ m³General populationLocalDNEL inhalationShort term inhalation859.7 mg/ populationGeneral populationSystemicDNEL inhalationShort term inhalation960 mg/m³WorkersLocalDNEL systemicShort term inhalation960 mg/m³WorkersSystemicDNEL inhalationShort term inhalation960 mg/m³WorkersSystemicDNEL inhalationShort term inhalation960 mg/m³WorkersSystemicDNEL inhalationDNEL inhalationLong term oral inhalation1.6 mg/kg populationGeneral populationSystemicDNEL inhalationLong term inhalation1.4 mg/m³General populationSystemicDNEL inhalationLong term Dermal inhalation108 mg/kg bw/dayGeneral populationSystemicDNEL inhalationDNEL inhalationIon gr/kg bw/dayGeneral populationSystemicDNEL inhalationDNEL inhalationShort term inhalation289 mg/m³WorkersSystemic4-methylpentan-2-oneDNEL DNEL inhalationLong term Oral inhalation4.2 mg/kg populationGeneral systemicSystemic0NEL inhalationLong term Oral inhalation4.2 mg/kg populationGeneral systemicSystemic0NEL inhalationDNEL inhalationLong term Dermal inhalation4.2 mg/kg population <td< td=""><td></td><td>DNEL</td><td></td><td>480 mg/m³</td><td>Workers</td><td>Local</td></td<> | | DNEL | | 480 mg/m ³ | Workers | Local |
| Inhalationm³ Sort termpopulation Sort termsystemic populationDNELShort term960 mg/m³WorkersLocalInhalationDNELShort term960 mg/m³WorkersLocalDNELShort term960 mg/m³WorkersSystemicInhalationDNELLong term Oral1.6 mg/kgGeneralSystemicInhalationDNELLong term Oral1.6 mg/kgGeneralSystemicpopulationDNELLong term Oral1.6 mg/kgGeneralSystemicDNELLong term Oral1.6 mg/kgGeneralSystemicDNELLong term Oral1.6 mg/kgGeneralSystemicDNELLong term Oral1.6 mg/kgGeneralSystemicDNELLong term Dermal108 mg/kgGeneralSystemicInhalationDNELLong term Dermal180 mg/kgSystemicDNELLong term Dermal180 mg/kgWorkersSystemicbw/dayDNELShort term289 mg/m³WorkersSystemicInhalationDNELShort term289 mg/m³WorkersSystemicInhalationDNELLong term Oral4.2 mg/kgGeneralSystemicInhalationDNELLong term Oral4.2 mg/kgGeneralSystemicInhalationDNELLong term Dermal11.8 mg/kgGeneralSystemicInhalationDNELLong term Dermal11.8 mg/kgGeneralSystemicInhalatio | | | | 850.7 mg/ | Conoral | |
| PNELShort term859.7 mg/ m³General populationSystemicInhalationDNELShort term960 mg/m³WorkersLocalInhalationDNELShort term960 mg/m³WorkersSystemicInhalationDNELShort term960 mg/m³WorkersSystemicInhalationInhalationInhalationpopulationSystemicInhalationInhalationInhalationpopulationSystemicDNELLong term Oral1.6 mg/kgGeneralSystemicInhalationDNELLong term17 mg/m³GeneralSystemicDNELLong termTr mg/m³WorkersSystemicDNELLong term Dermal108 mg/kgGeneralSystemicDNELLong term Dermal108 mg/kgpopulationSystemicDNELLong term Dermal108 mg/kgGeneralSystemicDNELLong term Dermal108 mg/kgWorkersSystemicDNELLong term Dermal108 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kgGeneralSystemicInhalationDNELLong term Oral4.2 mg/kgGeneralSystemicDNELLong term Dermal11.8 mg/WorkersSystemicDNELLong term Dermal11.8 mg/GeneralSystemicDNELLong term Dermal14.7 mg/m³GeneralSystemicDNELLong term14.7 mg/m³GeneralSystemic< | | DNEL | | | | LUCAI |
| Inhalationm³ 960 mg/m³population WorkersLocalDNELShort term Inhalation960 mg/m³WorkersLocalDNELShort term Inhalation960 mg/m³WorkersSystemicDNELShort term Inhalation1.6 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation1.4 mg/m³General general populationSystemicDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersLocal4-methylpentan-2-oneDNELLong term Dermal Inhalation4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation1.8 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation4.2 mg/kg gopulationSystemicSystemicDNELLong term Dermal Inhalation11.8 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation11.8 mg/kg gopulationGeneral populationSystemicDNELLong term Dermal Inhalation11.8 mg/kg gopulationGeneral gopul | | DNEL | | | | Systemic |
| PrescriptionDNELShort term Inhalation960 mg/m³WorkersLocalReaction mass of ethylbenzene and xyleneDNELShort term Inhalation960 mg/m³WorkersSystemicDNELShort term Inhalation960 mg/m³WorkersSystemicDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation14.8 mg/m³General populationSystemicDNELLong term Inhalation77 mg/m³WorkersSystemicDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation180 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersSystemicA-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicA-methylpentan-2-oneDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemic populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal11.8 mg/ populationSystemicSystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term Dermal14.7 mg/m³General populationSystemic | | | | | | |
| Reaction mass of ethylbenzene and xyleneDNELShort term Inhalation960 mg/m³WorkersSystemicDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation14.8 mg/m³General populationSystemicDNELLong term Inhalation77 mg/m³WorkersSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELLong term Oral Inhalation289 mg/m³WorkersSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | | DNEL | | | | Local |
| Reaction mass of ethylbenzene and xyleneDNELInhalation Long term Oral1.6 mg/kg bw/dayGeneral populationSystemicDNELLong term14.8 mg/m³General populationSystemicDNELLong term77 mg/m³WorkersSystemicDNELLong term77 mg/m³WorkersSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersSystemicDNELShort term Inhalation289 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicDNELLong term Dermal14.7 mg/m³General populationSystemic | | | | _ | | |
| Reaction mass of ethylbenzene and xyleneDNEL DNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSystemicDNEL InhalationLong term Inhalation14.8 mg/m³General gopulationSystemicDNEL InhalationLong term Inhalation77 mg/m³WorkersSystemicDNEL InhalationLong term Dermal bw/day108 mg/kg bw/dayGeneral populationSystemicDNEL InhalationLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNEL InhalationLong term Dermal180 mg/kg bw/dayWorkersSystemicDNEL InhalationShort term Inhalation289 mg/m³ bw/dayWorkersSystemicDNEL InhalationDNEL InhalationLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNEL InhalationLong term Dermal Inhalation4.2 mg/kg bw/dayGeneral populationSystemicDNEL InhalationLong term Dermal Inhalation11.8 mg/ bw/dayWorkersSystemicDNEL InhalationLong term Dermal Inhalation11.8 mg/ bw/dayWorkersSystemicDNEL InhalationLong term Dermal Inhalation14.7 mg/m³ GeneralGeneral populationSystemicDNEL InhalationLong term Inhalation14.7 mg/m³ GeneralGeneral SystemicSystemic | | DNEL | | 960 mg/m ³ | Workers | Systemic |
| xylenebw/daypopulationDNELLong term14.8 mg/m³General populationSystemicDNELLong term77 mg/m³WorkersSystemicDNELLong term Dermal108 mg/kgGeneral populationSystemicDNELLong term Dermal108 mg/kgGeneral populationSystemicDNELLong term Dermal108 mg/kgWorkersSystemicDNELLong term Dermal180 mg/kgWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersSystemicDNELShort term Inhalation289 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kgGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal11.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | | | | 4.0 | | |
| DNELLong term Inhalation14.8 mg/m³General populationSystemicDNELLong term Inhalation77 mg/m³WorkersSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal108 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersLocalDNELShort term Inhalation289 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemic4-methylpentan-2-oneDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | • | DNEL | Long term Oral | | | Systemic |
| Inhalation Long term Inhalation77 mg/m³population WorkersSystemicDNEL Long term Dermal108 mg/kg bw/dayGeneral populationSystemicDNEL DNELLong term Dermal108 mg/kg bw/dayWorkersSystemicDNEL DNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNEL InhalationShort term Inhalation289 mg/m³WorkersLocalDNEL InhalationDNEL DNELShort term Inhalation289 mg/m³WorkersSystemicDNEL DNEL DNEL DNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNEL DNEL DNEL DNEL DNEL DNEL DNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Dermal11.8 mg/ bw/dayWorkersSystemicDNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term14.7 mg/m³ General GeneralLocal | xyiene | | Long torm | | | Svetomie |
| DNELLong term Inhalation77 mg/m³WorkersSystemicDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersLocal4-methylpentan-2-oneDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | | DINEL | | 14.0 mg/m | | Systemic |
| InhalationInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation289 mg/m³WorkersLocalA-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersSystemicDNELDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicDNELLong term Dermal11.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | | DNEL | | 77 ma/m³ | | Systemic |
| DNELLong term Dermal108 mg/kg bw/dayGeneral population WorkersSystemicDNELLong term Dermal180 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation DNELShort term Inhalation289 mg/m³WorkersLocal4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal14.7 mg/m³General populationSystemic | | | | <u></u> | | - , |
| DNELLong term Dermal180 mg/kg bw/dayWorkersSystemic4-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersLocal4-methylpentan-2-oneDNELCong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicSystemicDNELLong term Dermal11.7 mg/m³General populationSystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationSystemic | | DNEL | | 108 mg/kg | General | Systemic |
| 4-methylpentan-2-oneDNELShort term Inhalation DNELbw/day 289 mg/m³WorkersLocal4-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersSystemicDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/daySystemicDNELLong term Dermal14.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General generalSystemic | | | _ | | | - |
| DNELShort term Inhalation289 mg/m³WorkersLocal4-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersSystemic0NELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemic0NELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemic0NELLong term Dermal11.8 mg/ kg bw/daySystemic0NELLong term Dermal11.7 mg/m³General populationSystemic0NELLong term14.7 mg/m³General populationLocal | | DNEL | Long term Dermal | | Workers | Systemic |
| 4-methylpentan-2-oneInhalation Short term Inhalation289 mg/m³WorkersSystemic4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal11.7 mg/m³General populationSystemicDNELLong term14.7 mg/m³General populationLocalDNELLong term14.7 mg/m³General SystemicSystemic | | | Chart to me | | \ \ / a w/ <i>c</i> = == | |
| A-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersSystemic4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term Dermal11.7 mg/m³General populationLocalDNELLong term14.7 mg/m³General populationSystemic | | DNEL | | 289 mg/m ³ | Workers | Local |
| 4-methylpentan-2-one Inhalation Inhalation 4.2 mg/kg General Systemic DNEL Long term Oral 4.2 mg/kg General Systemic DNEL Long term Dermal 4.2 mg/kg General Systemic DNEL Long term Dermal 4.2 mg/kg General Systemic DNEL Long term Dermal 11.8 mg/ Workers Systemic DNEL Long term 14.7 mg/m³ General Local DNEL Long term 14.7 mg/m³ General Systemic | | | | 280 mg/m^3 | Workers | Systemic |
| 4-methylpentan-2-one DNEL Long term Oral 4.2 mg/kg General Systemic DNEL Long term Dermal 4.2 mg/kg General Systemic DNEL Long term Dermal 4.2 mg/kg General Systemic bw/day population DNEL Long term Dermal 11.8 mg/ Workers Systemic DNEL Long term 14.7 mg/m³ General Local population DNEL Long term 14.7 mg/m³ General Systemic | | DINCL | | 209 mg/m | WUIKEIS | Systemic |
| DNELLong term Dermalbw/daypopulationDNELLong term Dermal4.2 mg/kgGeneralSystemicbw/daypopulationbw/daypopulationSystemicDNELLong term Dermal11.8 mg/WorkersSystemicDNELLong term14.7 mg/m³GeneralLocalDNELLong term14.7 mg/m³GeneralSystemic | 4-methylpentan-2-one | DNEL | | 4.2 mg/kg | General | Systemic |
| DNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term Inhalation14.7 mg/m³General populationLocal populationDNELLong term14.7 mg/m³General generalLocal population | | | | | | |
| DNELLong term Dermalbw/daypopulationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystemicDNELLong term14.7 mg/m³General populationLocal populationDNELLong term14.7 mg/m³GeneralSystemic | | DNEL | Long term Dermal | | | Systemic |
| kg bw/daykg bw/dayDNELLong term14.7 mg/m³GeneralLocalInhalationDNELLong term14.7 mg/m³GeneralSystemic | | | | bw/day | population | |
| DNELLong term14.7 mg/m³GeneralLocalInhalationpopulationDNELLong term14.7 mg/m³GeneralSystemic | | DNEL | Long term Dermal | • | Workers | Systemic |
| InhalationpopulationDNELLong term14.7 mg/m³GeneralSystemic | | | | | | |
| DNEL Long term 14.7 mg/m³ General Systemic | | DNEL | | 14.7 mg/m ³ | | Local |
| | | | | 1 | population | |
| | | | | 117 mailer 3 | | Sustamia |
| | | | Long term | 14.7 mg/m ³ | General | Systemic |
| | e of issue/Date of revision : 27-1 | | Long term | | General | Systemic |



| SECTION 8: Exposure controls/personal protection | | | | | |
|--|------|---------------------------------------|------------------------|------------|----------|
| | DNEL | Long term | 83 mg/m ³ | Workers | Local |
| | | Inhalation | U U | | |
| | DNEL | Long term | 83 mg/m ³ | Workers | Systemic |
| | | Inhalation | Ũ | | , |
| | DNEL | Short term | 155.2 mg/ | General | Local |
| | | Inhalation | m³ Ö | population | |
| | DNEL | Short term | 155.2 mg/ | General | Systemic |
| | | Inhalation | m³ | population | , |
| | DNEL | Short term | 208 mg/m ³ | Workers | Local |
| | | Inhalation | Ū | | |
| | DNEL | Short term | 208 mg/m ³ | Workers | Systemic |
| | | Inhalation | Ũ | | , |
| Hexanoic acid, 2-ethyl-, zinc salt, | DNEL | Long term Oral | 0.83 mg/ | General | Systemic |
| basic | | Ŭ | kg bw/day | population | , |
| | DNEL | Long term | 2.5 mg/m ³ | General | Systemic |
| | | Inhalation | • | population | - |
| | DNEL | Long term Dermal | 3.21 mg/ | General | Systemic |
| | | , , , , , , , , , , , , , , , , , , , | kg bw/day | population | - |
| | DNEL | Long term | 5 mg/m ³ | Workers | Systemic |
| | | Inhalation | - | | |
| | DNEL | Long term Dermal | 6.41 mg/ | Workers | Systemic |
| | | - | kg bw/day | | |
| propylidynetrimethanol | DNEL | Long term Oral | 1.68 mg/ | General | Systemic |
| | | | kg bw/day | population | |
| | DNEL | Long term Dermal | 1.68 mg/ | General | Systemic |
| | | | kg bw/day | population | |
| | DNEL | Long term Dermal | 2.79 mg/ | Workers | Systemic |
| | | | kg bw/day | | |
| | DNEL | Long term | 5.03 mg/m ³ | | Systemic |
| | | Inhalation | | population | |
| | DNEL | Long term | 19.54 mg/ | Workers | Systemic |
| | | Inhalation | m³ | | |
| | DNEL | Short term Oral | 50 mg/kg | General | Systemic |
| | | | bw/day | population | |
| | DNEL | Short term Dermal | 83.3 mg/ | General | Systemic |
| | | | kg bw/day | population | |
| | DNEL | Short term Dermal | 138.8 mg/ | Workers | Systemic |
| | | | kg bw/day | | |
| | DNEL | Short term | 925 mg/m ³ | General | Systemic |
| | | Inhalation | | population | |
| | DNEL | Short term | 3037.3 mg/ | Workers | Systemic |
| | | Inhalation | m³ | | |

PNECs

No PNECs available.

Date of previous issue

| 8.2 Exposure controls Appropriate engineering controls | ventilation or other engi contaminants below an controls also need to ke | ventilation. Use process enclosure neering controls to keep worker ex y recommended or statutory limits. ep gas, vapor or dust concentratio vplosion-proof ventilation equipmen | posure to airborne The engineering ns below any lower |
|--|--|--|---|
| Individual protection meas | ures | | |
| Hygiene measures | before eating, smoking Appropriate techniques Contaminated work clo | and face thoroughly after handling and using the lavatory and at the e should be used to remove potentia hing should not be allowed out of the pefore reusing. Ensure that eyewas e workstation location. | nd of the working period. Ily contaminated clothing. he workplace. Wash |
| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
| Date of previous issue | : 21-10-2022 | 10/20 | AkzoNobel |

10/20

:21-10-2022

| SECTION 8: Exposure controls/personal protection | | | | |
|--|---|--|--|--|
| Eye/face protection | : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields. | | | |
| Skin protection | | | | |
| Hand protection | : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. | | | |
| | When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time >480 minutes according to EN374) is recommended. Recommended gloves: Viton ® or Nitrile, thickness \geq 0.38 mm. When only brief contact is expected, a glove with protection class of 2 or higher (breakthrough time >30 minutes according to EN374) is recommended. Recommended gloves: Nitrile, thickness \geq 0.12 mm. Gloves should be replaced regularly and if there is any sign of damage to the glove material. | | | |
| | The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance. | | | |
| | The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment. | | | |
| Body protection | : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods. | | | |
| Other skin protection | Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. | | | |
| Respiratory protection | : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use. | | | |
| Environmental exposure controls | : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels. | | | |

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

| <u>Appearance</u> | |
|------------------------------|-------------------|
| Physical state | : Liquid. |
| Color | : Gray. |
| Odor | : Characteristic. |
| Odor threshold | : Not available. |
| рН | : Not available. |
| Melting point/freezing point | : Not available. |
| | |

| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
|--------------------------------|--------------|----------------|----------|
| Date of previous issue | : 21-10-2022 | 11/20 | AkzoNobe |

SECTION 9: Physical and chemical properties

| · · · · · · · · · · · · · · · · · · · | | the second se |
|---|---|---|
| Initial boiling point and boiling range | : | Not available. |
| Flash point | : | Closed cup: 28°C |
| Evaporation rate | : | Not available. |
| Flammability (solid, gas) | : | Not available. |
| Upper/lower flammability or explosive limits | : | Not available. |
| Vapor pressure | : | Not available. |
| Vapor density | : | Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 2.6 (Air = 1) |
| Density | : | 1.27 g/cm ³ |
| Solubility(ies) | : | Insoluble in the following materials: cold water. |
| Partition coefficient: n-octanol/ water | : | Not available. |
| Auto-ignition temperature | : | Not available. |
| Decomposition temperature | : | Not available. |
| Viscosity | : | Kinematic (room temperature): 1.97 cm²/s Kinematic (40°C): 1.01 cm²/s |

SECTION 10: Stability and reactivity

| 10.1 Reactivity | : No specific test data related to reactivity available for this product or its ingredients. |
|--|---|
| 10.2 Chemical stability | : The product is stable. |
| 10.3 Possibility of hazardous reactions | : Under normal conditions of storage and use, hazardous reactions will not occur. |
| 10.4 Conditions to avoid | : Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition. |
| 10.5 Incompatible materials | : Reactive or incompatible with the following materials: oxidizing materials |
| 10.6 Hazardous decomposition products | : Under normal conditions of storage and use, hazardous decomposition products should not be produced. |

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|--|-----------------------|------------|--------------------|----------|
| n-butyl acetate | LC50 Inhalation Gas. | Rat | 390 ppm | 4 hours |
| | LC50 Inhalation Vapor | Mouse | 6 g/m ³ | 2 hours |
| | LD50 Dermal | Rabbit | >17600 mg/kg | - |
| | LD50 Intraperitoneal | Mouse | 1230 mg/kg | - |
| | LD50 Oral | Guinea pig | 4700 mg/kg | - |
| | LD50 Oral | Mouse | 6 g/kg | - |
| | LD50 Oral | Rabbit | 3200 mg/kg | - |
| | LD50 Oral | Rat | 10768 mg/kg | - |
| Reaction mass of ethylbenzene and xylene | LC50 Inhalation Gas. | Rat | 5000 ppm | 4 hours |
| 4-methylpentan-2-one | LD50 Intraperitoneal | Guinea pig | 800 mg/kg | - |
| e of issue/Date of revision | : 27-10-2022 | Versio | n : 1.02 | |
| e of previous issue | : 21-10-2022 | 12/20 | | AkzoNob |

SECTION 11: Toxicological information

| | LD50 Intraperitoneal | Mouse | 268 mg/kg | - |
|--|-----------------------|------------|------------------------|---------|
| | LD50 Intraperitoneal | Rat | 400 mg/kg | - |
| | LD50 Oral | Guinea pig | 1600 mg/kg | - |
| | LD50 Oral | Mouse | 1900 mg/kg | - |
| | LD50 Oral | Mouse | 2850 mg/kg | - |
| | LD50 Oral | Rat | 2080 mg/kg | - |
| | LD50 Oral | Rat | 4600 mg/kg | - |
| Hydrocarbons, C10-C13, n- alkanes, isoalkanes, cyclics, < 2% aromatics | LC50 Inhalation Vapor | Rat | 8500 mg/m ³ | 4 hours |
| | LD50 Oral | Rat | >6 g/kg | - |
| propylidynetrimethanol | LD50 Oral | Mouse | 13700 mg/kg | - |
| | LD50 Oral | Mouse | 14000 mg/kg | - |
| | LD50 Oral | Rat | 14100 mg/kg | - |
| | LD50 Oral | Rat | 14000 mg/kg | - |

Conclusion/Summary : Not available.

Irritation/Corrosion

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|-------------------------|--------------------------|---------|-------|---------------|-------------|
| p -butyl acetate | Eyes - Moderate irritant | Rabbit | - | 100 mg | - |
| - | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| Reaction mass of | Eyes - Mild irritant | Rabbit | - | 87 mg | - |
| ethylbenzene and xylene | | | | | |
| | Eyes - Severe irritant | Rabbit | - | 24 hours 5 | - |
| | | | | mg | |
| | Skin - Mild irritant | Rat | - | 8 hours 60 UI | - |
| | Skin - Moderate irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| | Skin - Moderate irritant | Rabbit | - | 100 % | - |
| 4-methylpentan-2-one | Eyes - Moderate irritant | Rabbit | - | 24 hours 100 | - |
| | | | | UI | |
| | Eyes - Severe irritant | Rabbit | - | 40 mg | - |
| | Skin - Mild irritant | Rabbit | - | 24 hours 500 | - |
| | | | | mg | |
| Conclusion/Summary | · Not available | | | 1 | |

| Conclusion/Summary | : Not available. |
|------------------------------|------------------------------|
| Sensitization | |
| Conclusion/Summary | : Not available. |
| <u>Mutagenicity</u> | |
| Conclusion/Summary | : Not available. |
| Carcinogenicity | |
| Conclusion/Summary | : Not available. |
| Reproductive toxicity | |
| Conclusion/Summary | : Not available. |
| Teratogenicity | |
| Conclusion/Summary | : Not available. |
| Specific target organ toxici | <u>ity (single exposure)</u> |

Product/ingredient name Category Route of **Target organs** exposure 2-ethoxy-1-methylethyl acetate Narcotic effects Category 3 n-butyl acetate Category 3 Narcotic effects 2-methoxy-1-methylethyl acetate Category 3 Narcotic effects Reaction mass of ethylbenzene and xylene Category 3 Respiratory tract irritation Category 3 Narcotic effects 4-methylpentan-2-one

| Date of issue/Date of revision | : 27-10-2022 |
|--------------------------------|--------------|
| Date of previous issue | : 21-10-2022 |



SECTION 11: Toxicological information

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|--|------------|-------------------|---------------|
| Reaction mass of ethylbenzene and xylene | Category 2 | - | - |

Aspiration hazard

| Product/ingredient name | Result |
|--|--|
| Reaction mass of ethylbenzene and xylene Hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, < 2% aromatics | ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 |

Information on the likely : Not available.

routes of exposure

Potential acute health effects

| Eye contact | : No known significant effects or critical hazards. |
|--------------|---|
| Inhalation | : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. |
| Skin contact | : May cause an allergic skin reaction. |
| Ingestion | : Can cause central nervous system (CNS) depression. |

Symptoms related to the physical, chemical and toxicological characteristics

| Eye contact | : No specific data. |
|--------------|---|
| Inhalation | : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness |
| Skin contact | : Adverse symptoms may include the following: irritation redness |
| Ingestion | : No specific data. |

Delayed and immediate effects and also chronic effects from short and long term exposure

| <u>Short term exposure</u> | | | | | | |
|--------------------------------|---------|---|------------------------|--------|-----------|------------------------|
| Potential immediate effects | : Not a | available. | | | | |
| Potential delayed effects | : Not a | available. | | | | |
| Long term exposure | | | | | | |
| Potential immediate effects | : Not a | available. | | | | |
| Potential delayed effects | : Not a | available. | | | | |
| Potential chronic health eff | ects | | | | | |
| Not available. | | | | | | |
| Conclusion/Summary | : Not a | available. | | | | |
| General | | e sensitized, a seve ery low levels. | ere allergic reactior | n may | occur whe | n subsequently exposed |
| Carcinogenicity | : No k | nown significant e | ffects or critical haz | ards. | | |
| Mutagenicity | : No k | nown significant e | ffects or critical haz | ards. | | |
| Reproductive toxicity | : No k | known significant ei | ffects or critical haz | ards. | | |
| Date of issue/Date of revision | : 27- | -10-2022 | Ve | ersion | : 1.02 | |
| Date of previous issue | :21- | -10-2022 | 14 | /20 | | AkzoNobel |
| | | | | | | |

SECTION 11: Toxicological information

Other information : Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

| Product/ingredient name | Result | Species | Exposure |
|-------------------------|--------------------------------------|---------------------------------|----------|
| -butyl acetate | Acute LC50 32 mg/l Marine water | Crustaceans - Artemia salina | 48 hours |
| | Acute LC50 100000 µg/l Fresh water | Fish - Lepomis macrochirus | 96 hours |
| | Acute LC50 18000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 185000 µg/l Marine water | Fish - Menidia beryllina | 96 hours |
| | Acute LC50 62000 µg/l Fresh water | Fish - Danio rerio | 96 hours |
| Reaction mass of | Acute LC50 13400 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| ethylbenzene and xylene | | | |
| 4-methylpentan-2-one | Acute LC50 505000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 540000 µg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| | Acute LC50 537000 µg/l Fresh water | Fish - Pimephales promelas - | 96 hours |
| | | Juvenile (Fledgling, Hatchling, | |
| | | Weanling) | |
| | Chronic NOEC 78 mg/l Fresh water | Daphnia - Daphnia magna | 21 days |
| | Chronic NOEC 168 mg/l Fresh water | Fish - Pimephales promelas - | 33 days |
| | | Embryo | - |
| propylidynetrimethanol | Acute EC50 13000000 µg/l Fresh water | Daphnia - Daphnia magna | 48 hours |
| | Acute LC50 14400000 µg/l Marine | Fish - Cyprinodon variegatus | 96 hours |
| | water | | |
| Conclusion/Summary | : Not available. | + | - |

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|--|--------|-------------|-----------|
| 2-ethoxy-1-methylethyl acetate | 0.76 | - | low |
| n-butyl acetate | 2.3 | - | low |
| 2-methoxy-1-methylethyl acetate | 1.2 | - | low |
| Reaction mass of ethylbenzene and xylene | 3.12 | 8.1 to 25.9 | low |
| 4-methylpentan-2-one | 1.9 | - | low |
| Hydrocarbons, C10-C13, n- alkanes, isoalkanes, cyclics, < 2% aromatics | - | 10 to 2500 | high |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | - | 60960 | high |
| propylidynetrimethanol | -0.47 | <1 | low |

| 12.4 Mobility in soil | |
|-----------------------|------|
| Soil/water partition | : No |
| opefficient // | |

.

Not available.

| coefficient (Koc) | | | |
|--------------------------------|------------------|----------------|-----------|
| Mobility | : Not available. | | |
| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | |
| Date of previous issue | : 21-10-2022 | 15/20 | AkzoNobel |

SECTION 12: Ecological information

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

| <u>Product</u> | |
|-------------------------|--|
| Methods of disposal | : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. |
| Hazardous waste | : The classification of the product may meet the criteria for a hazardous waste. |
| Disposal considerations | Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority. |

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

| Waste code | Waste designation |
|-------------------------|--|
| EWC 08 01 11* | waste paint and varnish containing organic solvents or other hazardous substances |
| Packaging | |
| Methods of disposal | : The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. |
| Disposal considerations | Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions. |
| Special precautions | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. |

SECTION 14: Transport information



| | ADI | R/RID | IMDG | IATA |
|--|------------|---|-------------------|--|
| 14.1 UN number | UN1263 | UN1263 | | UN1263 |
| 14.2 UN proper shipping name | PAINT | PAINT | | PAINT |
| 14.3 Transport hazard class(es) | 3 | 3 | | 3 |
| 14.4 Packing group | | | | III |
| 14.5 Environmental hazards | No. | No. | | No. |
| Additional informa ADR/RID IMDG | : <u>T</u> | <u>innel code</u> (D/E) <u>nergency schedules</u> F-E, | _S-E_ | |
| 14.6 Special preca user | up | | nat persons trans | ansport in closed containers that are porting the product know what to do in |
| 14.7 Transport in t according to IMO instruments | oulk : No | ot applicable. | | |

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH) Annex XIV - List of substances subject to authorization

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain

dangerous substances, mixtures and articles

Other EU regulations

| voc | : The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information. |
|---|--|
| VOC for Ready-for-Use Mixture | : Not applicable. |
| Industrial emissions (integrated pollution prevention and control) - Air | : Not listed |



SECTION 15: Regulatory information

Industrial emissions : Not listed (integrated pollution prevention and control) -

Water

or

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Seveso Directive

This product is controlled under the Seveso Directive.

Danger criteria

Category

P5c

P90

National regulations

Industrial use

: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.

| Product/ingredient name | List name | Name on list | Classification | Notes |
|--|---------------------|---|----------------|-------|
| -ethoxy-1-methylethyl acetate | DFG MAC-values list | 1-Ethoxy-2-propyl acetate | Listed | - |
| n-butyl acetate | DFG MAC-values list | n-Butyl acetate | Listed | - |
| 2-methoxy-1-methylethyl acetate | DFG MAC-values list | 1-Methoxypropyl- 2-acetate; Propylene glycol 1-methyl ether- 2-acetate | Listed | - |
| Reaction mass of ethylbenzene and xylene | DFG MAC-values list | Xylene (all isomers) | Listed | - |
| 4-methylpentan-2-one | DFG MAC-values list | 4-Methyl-2-pentanone; Hexone | Listed | - |
| Hydrocarbons, C10-C13, n- alkanes, isoalkanes, cyclics, < 2% aromatics | DFG MAC-values list | Naphtha (petroleum) hydrotreated, heavy; Hydrocarbon solvent C6–C13 dearomatised | Listed | - |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | DFG MAC-values list | Zinc and its inorganic compounds (inhalable fraction) / (respirable fraction) | Listed | - |

Storage class (TRGS 510) : 3

Hazardous incident ordinance

| Hazard class for water | : 2 |
|---|---|
| Technical instruction on air quality control | : TA-Luft Number 5.2.5: 44.1% |
| AOX | : The product contains organically bound halogens and can contribute to the AOX value in waste water. |

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.



SECTION 15: Regulatory information

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Europe : Not determined.

15.2 Chemical Safety

nical Safety : No Chemical Safety Assessment has been carried out.

Assessment

SECTION 16: Other information

Indicates information that has changed from previously issued version.

| Abbreviations and acronyms | ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group |
|----------------------------|--|
| | SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative |

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification | Justification |
|-------------------------|-----------------------|
| Flam. Liq. 3, H226 | On basis of test data |
| Skin Sens. 1, H317 | Calculation method |
| STOT SE 3, H336 | Calculation method |
| Aquatic Chronic 3, H412 | Calculation method |

Full text of abbreviated H statements

| H225 | | Highly flammable liquid and vapor. | | |
|--------------------------------|--------------|---|--|--|
| H226 | | Flammable liquid and vapor. | | |
| H304 | | May be fatal if swallowed and enters airways. | | |
| H312 | | Harmful in contact with skin. | | |
| H315 | | Causes skin irritation. | | |
| H317 | | May cause an allergic skin reaction. | | |
| H319 | | Causes serious eye irritation. | | |
| H332 | | Harmful if inhaled. | | |
| H335 | | May cause respiratory irritation. | | |
| H336 | | May cause drowsiness or dizziness. | | |
| H351 | | Suspected of causing cancer. | | |
| H361 | | Suspected of damaging fertility or the unborn child. | | |
| H361d | | Suspected of damaging the unborn child. | | |
| H361f | | Suspected of damaging fertility. | | |
| H373 | | May cause damage to organs through prolonged | May cause damage to organs through prolonged or repeated | |
| | | exposure. | | |
| H400 | | Very toxic to aquatic life. | | |
| H410 | | Very toxic to aquatic life with long lasting effects. | | |
| H411 | | Toxic to aquatic life with long lasting effects. | | |
| H412 | | Harmful to aquatic life with long lasting effects. | | |
| EUH066 | | Repeated exposure may cause skin dryness or c | racking. | |
| Date of issue/Date of revision | : 27-10-2022 | Version : 1.02 | | |
| Date of previous issue | : 21-10-2022 | 19/20 AkzoNobe | | |

SECTION 16: Other information

Full text of eleccifications [CLD/CHS]

| Full text of classifications [CLP/GHS] | |
|--|--|
| Acute Tox. 4 | ACUTE TOXICITY - Category 4 |
| Aquatic Acute 1 | AQUATIC HAZARD (ACUTE) - Category 1 |
| Aquatic Chronic 1 | AQUATIC HAZARD (LONG-TERM) - Category 1 |
| Aquatic Chronic 2 | AQUATIC HAZARD (LONG-TERM) - Category 2 |
| Aquatic Chronic 3 | AQUATIC HAZARD (LONG-TERM) - Category 3 |
| Asp. Tox. 1 | ASPIRATION HAZARD - Category 1 |
| Carc. 2 | CARCINOGENICITY - Category 2 |
| Eye Irrit. 2 | SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2 |
| Flam. Liq. 2 | FLAMMABLE LIQUIDS - Category 2 |
| Flam. Liq. 3 | FLAMMABLE LIQUIDS - Category 3 |
| Repr. 2 | TOXIC TO REPRODUCTION - Category 2 |
| Skin Irrit. 2 | SKIN CORROSION/IRRITATION - Category 2 |
| Skin Sens. 1 | SKIN SENSITIZATION - Category 1 |
| Skin Sens. 1A | SKIN SENSITIZATION - Category 1A |
| STOT RE 2 | SPECIFIC TARGET ORGAN TOXICITY (REPEATED |
| | EXPOSURE) - Category 2 |
| STOT SE 3 | SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) - |
| | Category 3 |
| Date of printing | : 1 November 2022 |
| Date of issue/ Date of | : 27 October 2022 |
| revision | |
| Date of previous issue | : 21 October 2022 |
| Version | : 1.02 |
| | |

Unique ID

Notice to reader

FOR PROFESSIONAL USE ONLY

5

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

